<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Molecular biology and pathogenesis of von Hippel-Lindau disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Molecular biology and pathogenesis of von Hippel-Lindau disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Molecular biology and pathogenesis of von Hippel-Lindau disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sharon E Plon, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric Jonasch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors. VHL is diagnosed in approximately 1 in 36,000 people [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         The initial manifestations of disease can occur in childhood, adolescence, or later (mean age approximately 26 years). The spectrum of VHL-associated tumors includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemangioblastoma of the central nervous system
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retinal hemangioblastoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clear cell renal cell carcinoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pheochromocytoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endolymphatic sac tumors of the middle ear
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serous cystadenoma and neuroendocrine tumors of the pancreas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Papillary cystadenoma of the epididymis and broad ligament
        </p>
        <p>
        </p>
        <p>
         The molecular biology and pathogenesis of VHL disease, and the relationship of specific gene pathogenic variants to the clinical manifestations of the disease are reviewed here. The clinical features, diagnosis, and management of VHL disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MOLECULAR BIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The von Hippel-Lindau (
         <em>
          VHL
         </em>
         ) gene was mapped to chromosome 3p25 and cloned in the early 1990s [
         <a href="#rid4">
          4
         </a>
         ], with further research into the understanding of
         <em>
          VHL
         </em>
         gene function extending over the next 20 years [
         <a href="#rid5">
          5
         </a>
         ]. Its gene product, VHL, functions as a tumor suppressor protein [
         <a href="#rid6">
          6
         </a>
         ]. As with pathogenic variants in certain other tumor suppressor genes (eg, the retinoblastoma 1 [
         <em>
          RB1
         </em>
         ] gene), a "two-hit" model has been validated for VHL disease in which a germline loss of function variant inactivates one copy of the
         <em>
          VHL
         </em>
         gene in all cells. For VHL-associated tumors to develop, there must be loss of expression of the second normal allele through either somatic changes or deletion of the second allele, or through hypermethylation of its promoter. In sporadic renal cell cancers, inactivation of
         <em>
          VHL
         </em>
         through somatic changes of both alleles is very common.
        </p>
        <p>
         Major advances have been made over the last two decades in understanding the biology that underlies the formation of VHL-associated tumors [
         <a href="#rid6">
          6-10
         </a>
         ]. The VHL protein forms a stable complex with several other proteins, including elongin B, elongin C, and cullin 2. This complex targets several proteins for proteasomal degradation, thereby regulating their levels within the cell [
         <a href="#rid8">
          8-10
         </a>
         ]. The VHL component of this complex functions as an E3 ubiquitin ligase for the target molecules. Once bound to the VHL complex, the target molecules are covalently bound to ubiquitin, facilitating degradation by the proteasome.
        </p>
        <p>
         In addition to its function as an E3 ubiquitin ligase, VHL performs several other important cellular functions, including maintenance of the primary cilium, regulation of cytokinesis, control of microtubule function, extracellular matrix integrity, and regulation of the cell cycle. Pathogenic variants in the
         <em>
          VHL
         </em>
         gene have also been associated with congenital forms of polycythemia vera [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7106.html" rel="external">
          "Molecular pathogenesis of congenital erythrocytoses and polycythemia vera", section on 'Chuvash erythrocytosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Hypoxia-inducible factor 1 and 2
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypoxia-inducible factor 1 alpha (HIF1A) and 2 alpha (HIF2A) are two of the major proteins regulated by VHL  (
         <a class="graphic graphic_figure graphicRef127159" href="/z/d/graphic/127159.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. The 2019 Nobel Prize in Physiology or Medicine was awarded jointly to Dr. William G Kaelin, Dr. Peter J Ratcliffe, and Dr. Gregg L Semenza for their discovery of this molecular pathway [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         HIF1A and HIF2A are transcription factors that regulate a number of key cellular processes. Both HIF1A and HIF2A regulate glucose transport, lipid metabolism, pH homeostasis, and angiogenesis [
         <a href="#rid12">
          12
         </a>
         ]. In addition to erythropoietin, other factors known to be regulated through HIF1A and HIF2A include vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) beta, and transforming growth factor (TGF) alpha [
         <a href="#rid6">
          6,9,10
         </a>
         ]. Skewing of the ratio of HIF1A and HIF2A towards HIF2A may alter cell signaling and upregulate Myc activity in cells [
         <a href="#rid14">
          14
         </a>
         ]. The ratio switching is likely due to several factors. Hypoxia-associated factor (HAF) was shown to increase HIF2A transactivation [
         <a href="#rid15">
          15
         </a>
         ] and HIF1A instability [
         <a href="#rid16">
          16
         </a>
         ], resulting in a more aggressive cellular phenotype. In addition, in renal cell carcinoma tissue, preferential loss of chromosome 14q, the locus for the
         <em>
          HIF1A
         </em>
         gene, results in decreased levels of HIF1A [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         HIF1A and HIF2A also have unique targets. For example, HIF1A is a key transcription factor for glycolysis [
         <a href="#rid18">
          18
         </a>
         ], whereas HIF2A is involved in erythropoiesis through its ability to induce transcription of messenger RNA coding for erythropoietin [
         <a href="#rid19">
          19,20
         </a>
         ]. The role of HIF2 in erythropoiesis is discussed in detail elsewhere, but it will be briefly reviewed here to permit understanding of the events that occur in VHL disease. (See
         <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">
          "Regulation of erythropoiesis", section on 'Hypoxia-inducible factor and the response to hypoxia'
         </a>
         .)
        </p>
        <p>
         Transcriptional activation by HIF requires the heterodimerization and nuclear translocation of alpha and beta subunits [
         <a href="#rid21">
          21
         </a>
         ]. The beta subunit is not influenced by the oxygen tension and is not bound by the VHL protein complex. In contrast, the alpha subunits are sensitive to oxygen levels and are a substrate for the VHL protein complex. In the presence of normal oxygen tension, HIF1A and HIF2A are enzymatically hydroxylated [
         <a href="#rid21">
          21
         </a>
         ]. The hydroxylated HIF subunits are bound by the VHL protein complex and covalently linked to ubiquitin. Once this occurs, HIFA subunits are rapidly degraded by proteasomes  (
         <a class="graphic graphic_figure graphicRef53801" href="/z/d/graphic/53801.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         Under conditions of hypoxia, however, hydroxylation does not occur, and HIF1A and HIF2A are not bound to the VHL protein complex and cannot undergo ubiquitination. The levels of HIF1A and HIF2A rise, resulting in increased messenger RNA transcription of a variety of proteins, thus inducing a physiologic angiogenic response.
        </p>
        <p>
         In patients with VHL disease, loss of the sole functioning
         <em>
          VHL
         </em>
         allele in somatic tissues causes a situation analogous to hypoxia, despite the presence of normal oxygen tension [
         <a href="#rid6">
          6,7,10,22
         </a>
         ]. Pathogenic variants in the
         <em>
          VHL
         </em>
         gene can result in VHL failing to form the necessary protein complex to bind HIF1A and HIF2A, as many of the variants in type 1 VHL result in complete loss of VHL expression through nonsense-mediated decay. Alternatively, mutant VHL protein may result in failure of the binding site on the complex to recognize HIFA proteins [
         <a href="#rid9">
          9
         </a>
         ]. In either case, HIF1A and HIF2A are not linked to ubiquitin and are not degraded in proteasomes. Elevated levels of HIF1A and HIF2A can then induce abnormal production of the same factors that would be produced in conditions of physiologic hypoxia.
        </p>
        <p>
         In addition, VHL affects several other factors potentially involved in tumorigenesis that are not regulated through the HIF1A system. These targets include matrix metalloproteinases (MMPs) such as MMP1, MMP inhibitors, and atypical protein kinase C [
         <a href="#rid6">
          6,9
         </a>
         ].
        </p>
        <p>
         Although the mechanism of tumorigenesis remains unproven, the combined effect of various angiogenic factors and other growth factors may create an autocrine loop that provides an uncontrolled growth stimulus consistent with the highly vascular central nervous system tumors found in VHL patients [
         <a href="#rid23">
          23
         </a>
         ]. Additionally, VHL regulates several key cellular processes of which disruption may result in a malignant phenotype. These processes include extracellular matrix control, microtubule regulation, cilia centrosome cycle control, and cell cycle control.
        </p>
        <p class="headingAnchor" id="H13348203">
         <span class="h2">
          Extracellular matrix control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Presence of functional VHL is required to maintain proper assembly of an extracellular fibronectin matrix. VHL binds to and regulates fibronectin in a phosphorylation-dependent fashion [
         <a href="#rid24">
          24
         </a>
         ]. Pathogenic variants that preserve HIF regulation but are collagen IV binding incompetent demonstrate malignant behavior in some experimental models [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13348237">
         <span class="h2">
          Cilia centrosome regulation and microtubule control
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary cilium is a nonmotile organelle involved in mechanosensing, cell signaling, and regulation of cellular entry into mitosis [
         <a href="#rid26">
          26
         </a>
         ]. Loss of ciliary proteins or of signaling via canonical or noncanonical Wnt signaling pathways disrupts regulation of planar cell polarity and results in cyst formation [
         <a href="#rid27">
          27
         </a>
         ]. Coordinate inactivation of VHL and glycogen synthase kinase 3 beta (GSK3B) is sufficient to induce loss of primary cilium [
         <a href="#rid28">
          28
         </a>
         ] and, in animal models of
         <em>
          Vhlh
         </em>
         and
         <em>
          Pten
         </em>
         loss, increases cyst formation [
         <a href="#rid29">
          29
         </a>
         ]. VHL was found to bind to and stabilize microtubules [
         <a href="#rid30">
          30
         </a>
         ]. The binding of VHL to microtubules is regulated by glycogen synthase 3, which phosphorylates VHL at serine 68 and requires a priming phosphorylation event on serine 72 by casein kinase 1 [
         <a href="#rid31">
          31
         </a>
         ]. Loss of VHL or expression of mutated VHL in cells results in unstable astral microtubules, dysregulation of the spindle assembly checkpoint, and an increase in aneuploidy [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13348333">
         <span class="h2">
          Cell cycle control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adding back VHL to the
         <em>
          VHL
         </em>
         deficient 786-0 cell line results in reacquisition of cell cycle arrest upon serum withdrawal, with concomitant upregulation of p27 cyclin-dependent kinase inhibitor 1B (also referred to as p27) [
         <a href="#rid33">
          33
         </a>
         ]. Nuclear localization and intensity of p27 is inversely associated with tumor grade [
         <a href="#rid34">
          34
         </a>
         ]. VHL is responsible for S-phase kinase-associated protein 2 (SKP2) destabilization and concomitant upregulation of p27 after DNA damage [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         There are emerging data that suggest VHL may also regulate p53. It has been shown that p53 is an important regulator of mitotic checkpoints, and loss of p53 permits aneuploid cells to survive [
         <a href="#rid36">
          36
         </a>
         ]. VHL has been shown to bind to, stabilize, and transactivate p53 [
         <a href="#rid37">
          37
         </a>
         ], and this binding may be regulated by phosphorylation [
         <a href="#rid35">
          35,38
         </a>
         ]. Further work is required to dissect out the significance of these findings and their role in driving tumorigenesis.
        </p>
        <p class="headingAnchor" id="H13348666">
         <span class="h2">
          Animal models of VHL disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Satisfactory animal models for VHL disease have not yet been developed, and efforts are underway to define the necessary molecular steps required to replicate the human VHL disease phenotype in mice.
        </p>
        <p>
         Knockout of the homologous
         <em>
          Vhlh
         </em>
         gene in mice does not cause renal cell carcinoma formation or the development of hemangioblastomas [
         <a href="#rid39">
          39
         </a>
         ]. Attempts to generate murine homologues of human phenotypes have resulted in a replication of Chuvash polycythemia [
         <a href="#rid40">
          40
         </a>
         ], but a VHL p.Arg167Gln homologue did not generate renal cell carcinoma [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         The combination of
         <em>
          Vhlh
         </em>
         and
         <em>
          Pten
         </em>
         inactivation resulted in accelerated cyst formation [
         <a href="#rid29">
          29
         </a>
         ]. Similarly, a murine
         <em>
          Vhlh
         </em>
         conditional knockout, using a homeobox-B7-driven
         <em>
          Cre
         </em>
         driver specific for collecting ducts and a subset of distal tubules, exhibited widespread renal epithelial disruption, interstitial inflammation, and cystic lesions with severe fibrosis and significant hyperplasia [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         The addition of further gene knockouts associated with human renal cell carcinoma to the
         <em>
          Vhlh
         </em>
         knockout may result in mouse models that more accurately replicate the human VHL phenotype [
         <a href="#rid43">
          43-45
         </a>
         ]. Examples of such genes include
         <em>
          Bap1
         </em>
         [
         <a href="#rid43">
          43
         </a>
         ], a gene encoding a deubiquitinase lost in human renal cell carcinoma, and
         <em>
          Pbrm1
         </em>
         , a gene associated with chromatin remodeling [
         <a href="#rid44">
          44
         </a>
         ]. For example, mouse models with compound losses of
         <em>
          Vhlh
         </em>
         with either
         <em>
          Bap1
         </em>
         or
         <em>
          Pbrm1
         </em>
         have demonstrated neoplastic lesions [
         <a href="#rid43">
          43,44
         </a>
         ]. This study evaluated the effects of either a
         <em>
          Bap1
         </em>
         or a
         <em>
          Pbrm1
         </em>
         knockout in a
         <em>
          Vhl
         </em>
         null background [
         <a href="#rid44">
          44
         </a>
         ].
         <em>
          Pax8-Cre;Vhl
         </em>
         <em>
          <sup>
           F/F
          </sup>
         </em>
         <em>
          ;Bap1
         </em>
         <em>
          <sup>
           F/F
          </sup>
         </em>
         <sup>
         </sup>
         mice developed early neoplastic lesions but died at three months due to failure to thrive, whereas
         <em>
          Pax8-Cre;Vhl
         </em>
         <em>
          <sup>
           F/F
          </sup>
         </em>
         <em>
          ;Bap1
         </em>
         <em>
          <sup>
           F/+
          </sup>
         </em>
         mice lived approximately 15 months but also developed neoplastic renal lesions. Similarly,
         <em>
          Pax8-Cre;Vhl
         </em>
         <em>
          <sup>
           F/F
          </sup>
         </em>
         <em>
          ;Pbrm1
         </em>
         <em>
          <sup>
           F/F
          </sup>
         </em>
         mice had a 12-month life expectancy and developed large homogeneous tumors, whereas
         <em>
          Pax8-Cre;Vhl
         </em>
         <em>
          <sup>
           F/F
          </sup>
         </em>
         <em>
          ;Pbrm1
         </em>
         <em>
          <sup>
           F/+
          </sup>
         </em>
         mice had a 15-month life expectancy but did not develop tumors. This study also demonstrated that
         <em>
          Pax8-Cre;Vhl
         </em>
         <em>
          <sup>
           F/F
          </sup>
         </em>
         control mice (without knockouts in the
         <em>
          Bap1
         </em>
         or
         <em>
          Pbrm1
         </em>
         genes) did not develop any neoplastic lesions and had a life expectancy of 16 to 18 months. At this time, these mouse models are not sufficiently robust to represent VHL disease at an organ-specific level, including renal cell carcinoma, and further work is required to develop appropriate models.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOGENIC VARIANTS AND CLINICAL MANIFESTATIONS OF DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific germline disease-associated pathogenic variants or deletions of the von Hippel-Lindau (
         <em>
          VHL
         </em>
         )
         <em>
         </em>
         gene can influence the clinical manifestations of VHL disease [
         <a href="#rid6">
          6,46
         </a>
         ]. Deletions in
         <em>
          VHL
         </em>
         , and nonsense and frameshift variants appear to be more common in type I disease, while missense variants may be more common in type II disease [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p>
         These relationships can be illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pheochromocytoma
         </strong>
         – In a study of 138 families with VHL disease, large deletions and pathogenic variants in the
         <em>
          VHL
         </em>
         gene predicted to result in a truncated protein were associated with a much lower risk of pheochromocytoma than missense changes (6 versus 40 and 9 versus 59 percent at 30 and 50 years, respectively) [
         <a href="#rid47">
          47
         </a>
         ]. In particular, missense changes at codon 167 were associated with a particularly high risk of pheochromocytoma (over 80 percent by age 50). It is important to note that, although the risk for pheochromocytoma is diminished with deletions or other loss-of-function variants, the residual risk is high enough to warrant continued screening for pheochromocytoma in this patient population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal cell carcinoma
         </strong>
         – Data are conflicting on the association between specific germline variants and the development of renal cell carcinoma. As examples, in the study above, the cumulative probability of renal cell carcinoma in 138 families with VHL disease was similar in those with large deletions and intragenic loss of function
         <em>
          VHL
         </em>
         variants compared with those with missense variants [
         <a href="#rid47">
          47
         </a>
         ]. By contrast, in another report of 274 individuals in 126 unrelated families, gene abnormalities resulting in a truncated or absent protein, or large rearrangements led to an increased incidence of renal cell carcinoma compared with missense changes (81 versus 63 percent) [
         <a href="#rid48">
          48
         </a>
         ]. However, missense variants within two narrow cluster regions of the
         <em>
          VHL
         </em>
         gene were associated with higher incidence of renal cell carcinoma than missense changes elsewhere in the
         <em>
          VHL
         </em>
         gene.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retinal capillary hemangioblastomas
         </strong>
         – Correlations between
         <em>
          VHL
         </em>
         gene abnormality and the frequency of retinal capillary hemangioblastomas (RCHs) have also been observed [
         <a href="#rid49">
          49
         </a>
         ]. As an example, in a series of 196 patients, RCHs were twice as common among patients who had a missense variant than among those who had a gene abnormality resulting in a truncated protein.
        </p>
        <p>
        </p>
        <p>
         In patients with VHL-associated tumor presentations, the most common identification of pathogenic variants in the
         <em>
          VHL
         </em>
         gene is the result of directed genetic testing or hereditary cancer gene panels. The American College of Medical Genetics and Genomics (ACMG) publishes recommendations for the reporting of secondary findings (previously referred to as incidental findings) when performing clinical whole exome or genome sequencing [
         <a href="#rid50">
          50,51
         </a>
         ]. The
         <em>
          VHL
         </em>
         gene is included on the list of approximately 70 genes that are thought to be medically actionable. Thus, with the expansion of genomic sequencing, particularly in the diagnosis of young children with neurodevelopmental disorders, there has been an increase in the number of patients with VHL syndrome identified as a secondary finding. However, the ACMG secondary finding guidelines for exome or genome sequencing should not be interpreted to imply that the genes listed, including the
         <em>
          VHL
         </em>
         gene, are ready for general population screening without appropriate trials. One concern is identifying variants of uncertain significance when screening unaffected individuals, as penetrance when sampling the general public may not be known [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features of von Hippel-Lindau disease
         </strong>
         – Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant neoplasms, including clear cell renal cell carcinoma, hemangioblastomas, pheochromocytomas, and other rare tumors. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular biology and pathogenesis
         </strong>
         – The pathogenesis of VHL disease has been linked to germline (constitutional) variants in the
         <em>
          VHL
         </em>
         gene. VHL, the product of the
         <em>
          VHL
         </em>
         gene, is a tumor suppressor protein that performs a number of important cellular functions, including targeting proteins for proteasomal degradation, maintaining an intact primary cilium, and regulating the extracellular matrix. (See
         <a class="local">
          'Molecular biology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenic variants
         </strong>
         – The type of pathogenic variant in the
         <em>
          VHL
         </em>
         gene impacts the disease phenotype. In particular, patients with variants that encode missense changes have a significantly greater risk of developing pheochromocytoma compared with patients carrying loss-of-function variants or deletions. (See
         <a class="local">
          'Pathogenic variants and clinical manifestations of disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoxia-inducible factor 1 and 2 alpha
         </strong>
         – Hypoxia-inducible factor 1 alpha (HIF1A) and 2 alpha (HIF2A) are substrates for the product of the
         <em>
          VHL
         </em>
         gene. In the absence of VHL-induced degradation, HIF1A and HIF2A may contribute to increased levels of erythropoietin, vascular endothelial growth factor (VEGF), and other growth factors, providing a stimulus for tumor growth. (See
         <a class="local">
          'Hypoxia-inducible factor 1 and 2'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Animal models
         </strong>
         – Satisfactory animal models for VHL disease have not yet been developed. Efforts are underway to define the necessary molecular steps required to replicate the human VHL disease phenotype in mice. (See
         <a class="local">
          'Animal models of VHL disease'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003; 361:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997; 76:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22:4991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 2004; 287:F1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry RE, Krek W. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004; 10:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudler P, Urbancic M. The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel) 2022; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011; 12:9.
          </a>
         </li>
         <li class="breakAll">
          Press release: The Nobel Prize in Physiology or Medicine 2019. https://www.nobelprize.org/prizes/medicine/2019/press-release/ (Accessed on October 06, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh MY, Lemos R Jr, Liu X, Powis G. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 2011; 71:4015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol 2008; 28:7081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monzon FA, Alvarez K, Peterson L, et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 2011; 24:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23:9361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scortegagna M, Ding K, Oktay Y, et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 2003; 35:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruber M, Hu CJ, Johnson RS, et al. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A 2007; 104:2301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 2001; 98:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lolkema MP, Gervais ML, Snijckers CM, et al. Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem 2005; 280:22205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurban G, Hudon V, Duplan E, et al. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 2006; 66:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan J, Snell W. The primary cilium: keeper of the key to cell division. Cell 2007; 129:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simons M, Walz G. Polycystic kidney disease: cell division without a c(l)ue? Kidney Int 2006; 70:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thoma CR, Frew IJ, Hoerner CR, et al. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 2007; 9:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frew IJ, Thoma CR, Georgiev S, et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008; 27:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hergovich A, Lisztwan J, Barry R, et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003; 5:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hergovich A, Lisztwan J, Thoma CR, et al. Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol 2006; 26:5784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thoma CR, Toso A, Gutbrodt KL, et al. VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 2009; 11:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998; 95:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim J, Jonasch E, Alexander A, et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009; 15:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roe JS, Kim HR, Hwang IY, et al. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene 2011; 30:3127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Fang X, Baker DJ, et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci U S A 2010; 107:14188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roe JS, Kim H, Lee SM, et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai Y, Song M, Hakala K, et al. Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res 2011; 10:5175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 2001; 98:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hickey MM, Lam JC, Bezman NA, et al. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest 2007; 117:3879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CM, Hickey MM, Sanford CA, et al. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene 2009; 28:1694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchett TL, Bader HL, Henderson J, Hsu T. Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney. Oncogene 2015; 34:2631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SS, Gu YF, Wolff N, et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci U S A 2014; 111:16538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gu YF, Cohn S, Christie A, et al. Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov 2017; 7:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harlander S, Schönenberger D, Toussaint NC, et al. Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nat Med 2017; 23:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couch V, Lindor NM, Karnes PS, Michels VV. von Hippel-Lindau disease. Mayo Clin Proc 2000; 75:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996; 33:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallou C, Chauveau D, Richard S, et al. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat 2004; 24:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dollfus H, Massin P, Taupin P, et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 2002; 43:3067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017; 19:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACMG Board of Directors. The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2019; 21:1467.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5195 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2274658" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical features and natural history of von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12814730" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9413424" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8493574" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Identification of the von Hippel-Lindau disease tumor suppressor gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22304911" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hypoxia-inducible factors in physiology and medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15611513" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Role of VHL gene mutation in human cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12778166" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Regulation of angiogenesis by hypoxia: role of the HIF system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12209156" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Molecular basis of the VHL hereditary cancer syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15180922" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15350900" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35205407" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22169972" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : HIF1αand HIF2α: sibling rivalry in hypoxic tumour growth and progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22169972" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : HIF1αand HIF2α: sibling rivalry in hypoxic tumour growth and progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19061835" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21512133" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18838541" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21725288" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645546" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14608355" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17284606" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute postnatal ablation of Hif-2alpha results in anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15122348" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Oxygen sensing by HIF hydroxylases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11377966" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Activation of the HIF pathway in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11171960" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824109" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16452184" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17604715" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The primary cilium: keeper of the key to cell division.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816842" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Polycystic kidney disease: cell division without a c(l)ue?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17450132" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18497742" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12510195" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16847331" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19620968" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : VHL loss causes spindle misorientation and chromosome instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9448273" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118035" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358672" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20663956" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16678111" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : p53 stabilization and transactivation by a von Hippel-Lindau protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21942715" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Proteomic dissection of the von Hippel-Lindau (VHL) interactome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11171994" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17992257" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19252526" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25023703" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25359211" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28473526" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28553932" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10725953" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8730290" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15300849" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12202531" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23788249" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27854360" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31019278" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
